Medical Devices: Page 126


  • Pandemic habits could cause US health spending to decelerate over 2 decades, Deloitte predicts

    The consultancy's predictive modeling based its estimate on the rise of digital health products and more consumer engagement. Such a slowing contrasts more dire spending forecasts made prior to the COVID-19 crisis.

    By Rebecca Pifer Parduhn • Feb. 8, 2021
  • Medicare DME competitive bidding in doubt after failed round: analysts

    Cowen analysts said a recent report found steep rate hikes, leading them to conclude the program is no longer such a big threat to companies like Baxter, ResMed and Philips.

    By Feb. 8, 2021
  • Boston Scientific's Farapulse pulsed field ablation device. Explore the Trendlineâž”
    Image attribution tooltip
    Permission granted by Boston Scientific
    Image attribution tooltip
    Trendline

    New medical devices are reshaping the medtech industry

    From pulsed field ablation devices to glucose sensors and surgical robotics, new medical technologies are transforming patient care and how people manage their health.

    By MedTech Dive staff
  • Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    FDA OKs Signifier neurostim device for snoring, sleep apnea

    Signifier now faces the challenge of establishing eXciteOSA in the congested snoring and sleep apnea market targeted by companies including ResMed.

    By Feb. 8, 2021
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roundup: Medtech earnings season continues to show COVID-19 uncertainty

    BD, Quest Diagnostics and Roche all said they have a clearer view of the first quarter of 2021 but not the second half of the year, while Boston Scientific forecast electives pressure in the first quarter recovering in the second half.

    Feb. 5, 2021
  • Zimmer takes electives hit in Q4, to spin off spine, dental units

    "There's just no doubt that COVID, unfortunately, remains a challenge ... We're seeing the pandemic pressure and the surges continue and, frankly, worsen across pretty much all of our regions and markets," said CEO Bryan Hanson.

    By Feb. 5, 2021
  • BD Veritor system for rapid detection of SARS-CoV-2
    Image attribution tooltip
    Courtesy of BD/PRNewswire
    Image attribution tooltip

    BD posts better-than-expected COVID-19 test sales, but flagship Veritor revenues to slow

    Coronavirus testing revenues totaled $867 million, primarily made up by sales for the Veritor antigen test. Execs cited new virus variants and the potential for further slowing in elective care for a conservative forecast. 

    By Feb. 4, 2021
  • The FDA logo on a glass pane at the agency's campus in Silver Spring, Maryland.
    Image attribution tooltip
    Jacob Bell/MedTech Dive
    Image attribution tooltip

    FDA appoints first medical device cybersecurity chief

    University of Michigan professor Kevin Fu will serve a one-year term as acting cyber director at the Center for Devices and Radiological Health. Experts fear the chaos of the pandemic creates the perfect storm for hackers to exploit.

    By Feb. 3, 2021
  • Boston Scientific sees COVID-19 electives pressure in Q1, recovery in second half

    A hit of 7.7% in sales, driven by drops in neuromodulation and interventional cardiology, missed Wall Street expectations in the medtech's fourth quarter report.

    By Feb. 3, 2021
  • Death, injuries prompt FDA to call Boston Scientific ICD recall Class I event

    The device giant began recalling the subcutaneous implantable defibrillator system electrode late last year after learning of 26 serious injuries and one death associated with the device.

    By Feb. 3, 2021
  • A physician holds a telehealth session with a patient via computer.
    Image attribution tooltip
    [Photograph]. Retrieved from Regional Health Command Atlantic.
    Image attribution tooltip

    From COVID-19 EUAs to 'insidious' remote care risks: ECRI's top 10 medtech hazards

    Risks highlighted by the watchdog include FDA emergency use authorizations and the rapid adoption of telehealth, both of which have increased during the coronavirus pandemic.

    By Feb. 1, 2021
  • COVID-19's impacts on medtech industry operations
    Image attribution tooltip
    Adeline Kon/MedTech Dive
    Image attribution tooltip

    4 key trends for medtech in 2021

    With resurgence of the coronavirus and emergence of more contagious strains, COVID-19 challenges, but also opportunities, lie ahead for medical device and diagnostics companies.

    By Jan. 29, 2021
  • Low Medicare EKG device draft slams iRhythm, stock price sinks by over 30%

    Wall Street analysts questioned whether the lower-than-expected rates are final and what the prospects are for renegotiation. Shares of market leader iRhythm fell over 32% on Friday.

    By Updated Feb. 1, 2021
  • Deep Dive

    CGM, insulin pump players look to 2021 as watershed year for diabetes wearables market

    Insulet, Dexcom and Medtronic have product launches set for this year, and all look to capitalize on the recent skyrocketing of virtual care due to the coronavirus pandemic.

    By Jan. 29, 2021
  • iRhythm Zio XT
    Image attribution tooltip
    Permission granted by iRhythm Technologies
    Image attribution tooltip
    Q&A

    New iRhythm CEO on national pricing setback, Medtronic market expansion lessons

    Michael Coyle will try to build off the cardiac monitoring company's recent success amid a telehealth boom. Shares have jumped by over 175% in the last 12 months.

    By Jan. 28, 2021
  • Hospitals lost $20B by pausing electives last year

    The slowdown in elective care also hurt medtechs like Abbott and Johnson & Johnson. The industry expects declines to continue into 2021 after procedure volumes dropped again in the fourth quarter due to the virus resurgence.

    By Shannon Muchmore • Jan. 28, 2021
  • Edwards' US TAVR sales fall as COVID-19 disrupts referrals

    Analysts expected U.S. transcatheter aortic valve replacement sales to be flat in the fourth quarter but they fell by mid-single digits. Still, the company maintains guidance for global TAVR growth of 15-20% this year. 

    By Jan. 28, 2021
  • Image attribution tooltip
    Fotolia
    Image attribution tooltip

    Stryker falls short of Q4 sales amid electives pullback, robotics a bright spot

    Double-digit growth in China was offset by hits in business in the U.S. and Europe. CEO Kevin Lobo told investors after volumes rebounded through October, large declines began in November and December.

    By Jan. 27, 2021
  • A vial of BioNTech and Pfizer's coronavirus vaccine
    Image attribution tooltip
    Courtesy of BioNTech
    Image attribution tooltip

    Biden invokes DPA to combat supply shortages, but experts say it's no 'magic wand'

    AdvaMed early in the pandemic urged against using the Defense Production Act's powers, though some companies were more open. The device lobby last week asked the administration to coordinate with industry before taking action.

    By Matt Leonard • Jan. 27, 2021
  • England's NHS moves to boost access to Quidel, Roche, other medtech products

    To be a part of the National Health Services' MedTech Funding Mandate, companies must be able to make the claim that their products generate net savings in their first year of use.

    By Jan. 27, 2021
  • Abbott Laboratories
    Image attribution tooltip
    Courtesy of Abbott
    Image attribution tooltip

    Abbott Q4 beat driven by COVID-19 test demand, devices come in flat

    CEO Robert Ford said the company exited 2020 with "tremendous momentum" and forecast 35% growth for this year. 

    By Jan. 27, 2021
  • Image attribution tooltip
    Dollar Photo Club
    Image attribution tooltip

    Surmodics drug-coated balloon on par with Medtronic's in study

    The medtech is looking to distinguish itself from rivals with a lower dose, after a 2018 meta-analysis found a mortality risk for patients treated with paclitaxel-coated balloons or stents in the femoropopliteal artery of the leg.

    By Jan. 26, 2021
  • Ventilators, imaging drive GE healthcare profits up 27% as procedures even out

    "Regionally, public healthcare markets such as Europe and China have been stronger than private markets, particularly the U.S., India and Latin America," CFO Carolina Dybeck Happe told investors.

    By Jan. 26, 2021
  • Johnson & Johnson, credo wall
    Image attribution tooltip
    Permission granted by Johnson & Johnson
    Image attribution tooltip

    J&J misses Wall Street on hips, knees and spine amid global elective care slowdown

    CEO Alex Gorsky predicted challenges to persist in 2021 but suggested that improvement is in sight. "The resiliency and the ability of hospital systems to continue with elective surgeries has improved quite significantly," he said.

    By Jan. 26, 2021
  • Philips beats Q4 expectations as COVID-19 boosts connected care, slows procedures

    The Dutch conglomerate will continue to be active on the M&A front, CEO Frans van Houten told investors, after striking two deals in the space over the past month worth more than $3.4 billion.

    By Jan. 25, 2021
  • Deep Dive

    Abbott, Edwards focus on mitral valve as market projected to rival TAVR

    Companies have zeroed in on TAVR in recent years, but in 2021 and beyond, experts and industry are looking to the mitral market for the next big structural heart splash.

    By Jan. 25, 2021